Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
53.42
+2.11 (4.11%)
At close: Aug 22, 2025, 4:00 PM
53.20
-0.22 (-0.41%)
After-hours: Aug 22, 2025, 4:23 PM EDT
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Palvella Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $56.64, which forecasts a 6.03% increase in the stock price over the next year. The lowest target is $38 and the highest is $90.
Price Target: $56.64 (+6.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 7 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $52 → $66 | Strong Buy | Maintains | $52 → $66 | +23.55% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $38 → $75 | Strong Buy | Maintains | $38 → $75 | +40.40% | Aug 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $50 → $60 | Strong Buy | Maintains | $50 → $60 | +12.32% | Aug 15, 2025 |
| Raymond James | Raymond James | Buy Initiates $54 | Buy | Initiates | $54 | +1.09% | Aug 6, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $90 | Buy | Initiates | $90 | +68.48% | Aug 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.01
from -7.83
EPS Next Year
-3.15
from -3.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | 14.8M |
| Avg | n/a | n/a | 5.6M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.28 | -2.43 | -2.09 |
| Avg | -3.01 | -3.15 | -4.30 |
| Low | -3.29 | -3.95 | -8.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.